Hemifacial spasm

The first sign of hemifacial spasm is typically muscle movement in the patient's eyelid and around the eye. It can vary in intensity. == Causes ==

(The Seventh Cranial Nerve) Three theories exist to explain the facial nerve dysfunction found in hemifacial spasm. The first proposed theory is ephaptic transmission, which is electrical activity crossing from one demyelinated neuron to another resulting in a false synapse. The third theory or "Kindling theory" involves increased excitability of the facial nerve nucleus due to feedback from a damaged facial nerve. Hemifacial spasm is much more common in some Asian populations. == Diagnosis ==

There are several tests available to diagnose a case of hemifacial spasm. Diagnosis begins with a complete neurological exam, including an electromyography (EMG: a test that measures and records electrical activity generated in muscle at rest and in response to muscle contraction), magnetic resonance imaging (MRI: a test that uses magnetic waves to make pictures of structures inside the head), computed tomography (CT scan: a type of x-ray that uses a computer to make pictures of structures inside the head), and angiography (an x-ray exam of the blood vessels when they are filled with a contrast material). Studies have shown that the most effective method of hemifacial spasm screening is MRI. In one study, only 25% of the CT scans showed the abnormality in hemifacial spasm patients, whilst more than half of the MRI imaging demonstrated a vascular anomaly. MRI imaging is recommended as the initial screening procedure in the assessment of patients with hemifacial spasm. == Prevention ==

There is no known way to prevent hemifacial spasm. == Treatments ==

Mild cases of hemifacial spasm may be managed with sedation or carbamazepine (an anticonvulsant drug). Microsurgical decompression and botulinum toxin injections are the current main treatments used for hemifacial spasm. Microvascular decompression Microvascular decompression appears to be the most popular surgical treatment at present. Microvascular decompression relieves pressure on the facial nerve, which is the cause of most hemifacial spasm cases. Excellent to good results are reported in 80% or more cases with a 10% recurrence rate. In the present series approximately 10% had previously failed surgery. Serious complications can follow microsurgical decompressive operations, even when performed by experienced surgeons. These include cerebellar haematoma or swelling, brainstem infarction (blood vessel of the brain stem blocked), cerebral infarction (ischemic stroke resulting from a disturbance in the blood vessels supplying blood to the brain), subdural haematoma and intracerebral infarction (blockage of blood flow to the brain). Death or permanent disability (hearing loss) can occur in 2% of patients of hemifacial spasm. Botulinum toxin Observational data from studies (the updated review in 2020 did not find any randomized controlled trials) indicates that botulinum toxin is safe and effective in the treatment of hemifacial spasm with success rates of between 76 and 100%. The injections are administered as an outpatient or office procedure. Although side effects do occur, these are never permanent. Repeated injections over the years remain highly effective. Whilst the toxin is expensive, the cost of even prolonged courses of injections compares favourably with the cost of surgery. Patients with HFS should be offered a number of treatment options. Sometimes as a temporary measure, medical treatment can be offered to patients with very mild cases or those who are reluctant to have surgery or botulinum toxin injections. In young and fit patients, microsurgical decompression and botulinum injections should be discussed as alternative procedures. In the majority of cases, and especially in the elderly and the unfit, botulinum toxin injection is the treatment of first choice. Imaging procedures should be done in all unusual cases of hemifacial spasm and when surgery is contemplated. Patients with hemifacial spasm were shown to have decreased sweating after botulinum toxin injections. This was first observed in 1993 by Khalaf Bushara and David Park in the first demonstration of nonmuscular use of BTX-A. Bushara further showed the efficacy of botulinum toxin in treating hyperhidrosis (excessive sweating). BTX-A was later approved for the treatment of excessive underarm sweating. This is technically known as severe primary axillary hyperhidrosis – excessive underarm sweating with an unknown cause which cannot be managed by topical agents (see focal hyperhidrosis). == Epidemiology ==

The incidence of hemifacial spasm is approximately 0.8 per 100,000 persons. The estimated prevalence for women is 14.5 per 100,000 and 7.4 per 100,000 in men. Prevalence for hemifacial spasm increases with age, reaching 39.7 per 100,000 for those aged 70 years and older. One study divided 214 hemifacial patients based on the cause of the disease: primary hemifacial spasm, where the patients had a compression in the facial nerve at the end of the brainstem; and secondary hemifacial spasm, where the patients had peripheral facial palsy or nerve lesion due to tumors, demyelination, trauma or infection. The study found that 77% of cases were primary and 23% secondary. The study also found that the two sets of patients shared a similar age at onset, male to female ratios, and similar affected side. In another study of 2050 patients who had presented with hemifacial spasm between 1986 and 2009, only nine cases were caused by a cerebellopontine angle syndrome, an incidence of 0.44%. == History ==

The earliest descriptions about hemifacial spasm is by Shultze in 1875 and Gowers in 1899. The etiology of hemifacial spasm and location of the abnormality have been debated for more than a century. Additional advances in understanding the etiology and improving treatments for hemifacial spasm did not occur until the mid-seventies. In 1977, 47 cases of hemifacial spasm underwent microvascular decompression of the facial nerve using the operating microscope. The results illustrated nerve-vessel conflicts (or cholesteatoma) to be located at the root exit zone of the facial nerve in all cases. The root exit zone is where the central glial axonal insulation of the nerve ends and the peripheral nerve axonal myelination begins, this is known as The Obersteiner-Redlich zone. Biopsies of the root exit zone demonstrated degeneration of axons, denuded axis cylinder and interrupted myelin. The results of the experiment strengthened the theory that vascular compression of the facial nerve was the primary cause of hemifacial spasm, and proposed a specific region of the facial nerve where the effects of longstanding compression results in nerve dysfunction. == References ==